My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Biogen Idec (NQ:BIIB)

182.12 +1.37 (+0.76%)

Streaming Delayed Price Updated: 12:07 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

56 57 Next >

Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory? ↗

December 11, 2024

Super Micro faces potential delisting from Nasdaq 100 Index due to underperformance and auditing scandal. Uncertainty surrounds its future.

Via Benzinga

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown ↗

December 09, 2024

Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties.

Via Benzinga

This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

December 09, 2024

Via Benzinga

Assessing Biogen: Insights From 19 Financial Analysts ↗

December 09, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 02, 2024

Via Benzinga

Peeling Back The Layers: Exploring Biogen Through Analyst Insights ↗

November 14, 2024

Via Benzinga

Evaluating Biogen: Insights From 17 Financial Analysts ↗

November 04, 2024

Via Benzinga

Biogen Analysts Slash Their Forecasts After Q3 Results ↗

October 31, 2024

Via Benzinga

These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over ↗

November 26, 2024

Via The Motley Fool

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside ↗

November 20, 2024

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.

Via Benzinga

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

November 19, 2024

From Biogen Inc.

Via GlobeNewswire

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 ↗

November 18, 2024

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges.

Via Benzinga

Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum ↗

October 30, 2024

The biotech giant also raised full-year EPS guidance.

Via Investor's Business Daily

Looking Into Biogen's Recent Short Interest ↗

October 22, 2024

Via Benzinga

This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

November 18, 2024

Via Benzinga

Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 15, 2024

Via Benzinga

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

November 14, 2024

From Biogen Inc.

Via GlobeNewswire

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

This Kraft Heinz Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

October 31, 2024

Via Benzinga

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

October 30, 2024

From Biogen Inc.

Via GlobeNewswire

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

Biogen (BIIB) Q3 2024 Earnings Call Transcript ↗

October 30, 2024

BIIB earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook ↗

October 30, 2024

Biogen's Q2 revenue fell 3% to $2.47 billion exceeding estimates, with adjusted EPS of $4.08. Multiple sclerosis sales dipped, while new products buoyed performance.

Via Benzinga

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 29, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

October 29, 2024

From Biogen Inc.

Via GlobeNewswire

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

October 29, 2024

From Biogen Inc.

Via GlobeNewswire

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

October 28, 2024

Robin Kramer, Chief Accounting Officer, to Succeed Him

From Biogen Inc.

Via GlobeNewswire

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

October 26, 2024

From Biogen Inc.

Via GlobeNewswire

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

October 24, 2024

From Biogen Inc.

Via GlobeNewswire

This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock ↗

October 23, 2024

Fewer contenders means fewer constraints on expanding market share.

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.